misiu, thank you for your kind reply. I always en

misiu, thank you for your kind reply. I always enjoy your posts, your medical expertise, and your relentless focus on the positive science here.

To be clear, I do not think that everything that CYDY does is a bad look, and I am very pleased at the continuous good news on the scientific front.

Ultimately, though, I am in this investment to make money, and CYDY BOD and management are tasked, first and foremost, with maximizing shareholder value.

With that in mind, I think that, specifically with respect to the issue of the latest $600K raise, CYDY management looks bad because either:

1) management left the corporate coffers bare and needed to scrounge for $600K regardless of the impact to the SP, that is, shareholder value; or

2) didn't need the money, but did a favor for loyal shareholders without thinking through the impact to the SP, that is, shareholder value.

Trust me when I say that I do understand the medical implications here, as well as any lay person (i.e., non-doctor) can. The potential indications for which CCR5 antagonists may assist is astounding, and I am excited about leronlimab and its potential to help the sick.

Leronlimab's potential is all the more reason that I am dismayed when I see things that I perceive to be very poor management decisions, because poor management can both hurt shareholder value AND delay the time it takes to find out if leronlimab can help patients.

As just one example, if CYDY's finances were in order so that the GVHD trial wasn't put on hold for the last 6+ MONTHS due to finances (recall CYDY told us exactly that in SEC filings: GVHD delayed because no money), do you think leronlimab potentially could be assisting many GVHD patients right now on an accelerated approval basis? Or at least healing the GVHD patients that had enrolled in the trial?

We will never know the answer to that question, because CYDY had no money to fund the trial. And has no money to fund the colorectal cancer trial. Or the NASH trial. Or any other potential indication.

If leronlimab is what we hope it is, the delays in commencing each of those trials, and the resulting delay in ultimately (hopefully) obtaining approval for each new indication, will result in patients getting sicker or even dying when leronlimab could have helped.

As someone who cares so deeply about patients and medicine, it's important to understand that the SCIENCE of leronlimab will only prevail IF there is money to get there and that every delay in CYDY management getting the finances of the company in order is a delay that may, in the most extreme case, cost lives.

At some point, I would think you would become dismayed at the delays as well, if not for the sake of your pocketbook then for the sake of patients.

To maximize success, a biotech needs great science, great finances, and great management. CYDY definitely HAS the first, definitely DOES NOT have the second, and the jury is out, so to speak, on the third.

This post ended up being more long-winded that I first intended, and is not just directed at you. I think it's important that we all keep in mind the connection between management, finances, and science.

Management drives the finances. The finances drive the science.

Good luck to you and to us all!